Inovio Q3: $49.2M Loss, $48.4M Cash, Going Concern Pushed to Late Q4 2027
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio's Q3 loss of $49.2 million was mostly a $26.9 million non-cash warrant remeasurement; with $48.4 million in cash plus the $80.5 million November raise, management now sees funding into late Q4 2027, though going-concern doubt persists.
Key Events · Earnings and Guidance · INO
-
Q3 Loss Driven by Non-Cash Warrant Mark
Net loss of $49.2 million for the quarter included a $26.9 million non-cash change in fair value of warrant liabilities; nine-month net loss was $74.9 million versus $88.7 million a year earlier.
-
Cash Position and Runway Extended
Cash, cash equivalents and short-term investments were $48.4 million at September 30, 2026, with a $38.0 million working capital deficit; including the $80.5 million November offering and $10.9 million of subsequent warrant exercises, funding is expected into late Q4 2027.
-
Going Concern Doubt Remains
Management states substantial doubt exists about the ability to continue as a going concern beyond the fourth quarter of 2027 without additional financing.
-
Warrant Liability Swells to $70.0M
The liability-classified warrant balance rose to $70.0 million at September 30, 2026 from $29.1 million at December 31, 2025, reflecting new July and April 2026 warrants plus remeasurement — a non-cash item, not new cash obligations.
Analysis · INO · Life Sciences
The quarter's headline loss is mostly accounting noise: $26.9 million of the $49.2 million net loss is a non-cash mark-to-market on liability-classified warrants, driven by the share price, not by cash leaving the business or new dilution. What matters is the runway. With $48.4 million of cash and short-term investments at September 30 plus the $80.5 million November offering and $10.9 million of subsequent warrant exercises, management now says funding lasts into late Q4 2027 — later than the late Q1 2027 it flagged last quarter. Against that, the company still carries a $38.0 million working capital deficit and a $70.0 million warrant liability, and it must fund the VOCERYQ launch, priced at roughly $115,000 per dose ($460,000 for the four-dose series), plus a confirmatory study whose draft protocol is due to the FDA by end-2026. The going-concern warning remains, so another raise is likely before the runway ends.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.